Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Ichiro Kawada
Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors
Cancer Research
Cancer Research
Oncology
Multiple Nodular Lesions followingPneumocystispneumonia in a Non-Hiv Immunocompromised Patient
Clinical Case Reports
Medicine
Related publications
Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations
OncoTargets and Therapy
Oncology
Pharmacology
P2.13-29 IL-22 Confers Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer Bearing EGFR Gene Mutation and Amplification
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Acquired EGFR C797S Mutation Mediates Resistance to AZD9291 in Non–small Cell Lung Cancer Harboring EGFR T790M
Nature Medicine
Biochemistry
Medicine
Genetics
Molecular Biology
JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Molecular Imaging for Detection of Sensitivity and Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Clinical and Translational Imaging
Nuclear Medicine
Radiology
Imaging
Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR -Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)
Cancer
Cancer Research
Oncology
A Case of EGFR Mutant Lung Adenocarcinoma That Acquired Resistance to EGFR-tyrosine Kinase Inhibitors With MET Amplification and Epithelial-To-Mesenchymal Transition
OncoTargets and Therapy
Oncology
Pharmacology
ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer
Oncology in Clinical Practice
Oncology